will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dimenhydrinatedimenhydrinate and trimipramine both increase sedation. Use Caution/Monitor.diphenhydraminediphenhydramine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydramine and trimipramine both increase sedation. Use Caution/Monitor.diphenoxylate hcldiphenoxylate hcl and trimipramine both increase sedation. Use Caution/Monitor.dipipanonedipipanone and trimipramine both increase sedation. Use Caution/Monitor.dobutaminetrimipramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dofetilidedofetilide increases toxicity of trimipramine by QTc interval. Use Caution/Monitor.dolasetrontrimipramine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.donepezildonepezil increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopaminetrimipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopexaminetrimipramine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.doxepindoxepin and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepin and trimipramine both increase sedation. Use Caution/Monitor.doxylaminedoxylamine and trimipramine both increase sedation. Use Caution/Monitor.droperidoldroperidol and trimipramine both increase sedation. Use Caution/Monitor.duvelisibduvelisib will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.echothiophate iodideechothiophate iodide increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.efavirenzefavirenz will decrease the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.efavirenz will decrease the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.efavirenz and trimipramine both increase QTc interval. Use Caution/Monitor.elagolixelagolix will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak CYP2C19 inhibitor. Caution with sensitive CYP2C19 substrates.elagolix decreases levels of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.eletriptaneletriptan and trimipramine both increase serotonin levels. Modify Therapy/Monitor Closely.eliglustateliglustat increases levels of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.eliglustat and trimipramine both increase QTc interval. Use Caution/Monitor.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.encorafenibencorafenib, trimipramine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.entrectinibentrectinib and trimipramine both increase QTc interval. Use Caution/Monitor.ephedrinetrimipramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trimipramine increases effects of ephedrine by unknown mechanism. Use Caution/Monitor.epinephrinetrimipramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trimipramine increases effects of epinephrine by unknown mechanism. Use Caution/Monitor.epinephrine inhaledtrimipramine and epinephrine inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Tricyclic antidepressants may potentiate epinephrine effect on cardiovascular system.epinephrine racemictrimipramine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trimipramine increases effects of epinephrine racemic by unknown mechanism. Use Caution/Monitor.ergotaminetrimipramine and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.eribulineribulin and trimipramine both increase QTc interval. Use Caution/Monitor.escitalopramescitalopram increases toxicity of trimipramine by QTc interval. Use Caution/Monitor.esketamine intranasalesketamine intranasal, trimipramine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.eslicarbazepine acetateeslicarbazepine acetate will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.estazolamestazolam and trimipramine both increase sedation. Use Caution/Monitor.ethanoltrimipramine and ethanol both increase sedation. Use Caution/Monitor.etomidateetomidate and trimipramine both increase sedation. Use Caution/Monitor.ezogabineezogabine, trimipramine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.fedratinibfedratinib will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2E1 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.fedratinib will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2C19 substrates as necessary.fedratinib will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.fenfluraminetrimipramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trimipramine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.fenfluramine, trimipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome.fesoterodinefesoterodine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.fexinidazolefexinidazole will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.fingolimodfingolimod and trimipramine both increase QTc interval. Use Caution/Monitor.flavoxateflavoxate and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.flecainidetrimipramine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.fluoxetinetrimipramine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.fluphenazinefluphenazine and trimipramine both increase sedation. Use Caution/Monitor.flurazepamflurazepam and trimipramine both increase sedation. Use Caution/Monitor.fluvoxaminefluvoxamine and trimipramine both increase QTc interval. Modify Therapy/Monitor Closely.formoteroltrimipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.foscarnettrimipramine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.frovatriptanfrovatriptan and trimipramine both increase serotonin levels. Modify Therapy/Monitor Closely.gabapentingabapentin, trimipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilgabapentin enacarbil, trimipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.galantaminegalantamine increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.ganaxolonetrimipramine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacingemifloxacin and trimipramine both increase QTc interval. Use Caution/Monitor.gilteritinibgilteritinib and trimipramine both increase QTc interval. Use Caution/Monitor.glycopyrrolateglycopyrrolate and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.trimipramine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor.glycopyrrolate inhaledglycopyrrolate inhaled and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.trimipramine increases levels of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor.glycopyrronium tosylate topicalglycopyrronium tosylate topical, trimipramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.granisetrongranisetron and trimipramine both increase QTc interval. Use Caution/Monitor.haloperidolhaloperidol and trimipramine both increase sedation. Use Caution/Monitor.henbanehenbane and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropinehomatropine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine Ahuperzine A increases and trimipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrocodonehydrocodone, trimipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.hydromorphonehydromorphone and trimipramine both increase sedation. Use Caution/Monitor.hydroxyzinehydroxyzine and trimipramine both increase sedation. Use Caution/Monitor.hydroxyzine and trimipramine both increase QTc interval. Use Caution/Monitor.hyoscyaminehyoscyamine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayhyoscyamine spray and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.iloperidonetrimipramine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.iloperidone and trimipramine both increase sedation. Use Caution/Monitor.iloperidone increases levels of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.imipramineimipramine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.imipramine and trimipramine both increase sedation. Use Caution/Monitor.indacaterol, inhaledindacaterol, inhaled, trimipramine. QTc interval. Use Caution/Monitor. Indacaterol should be administered with extreme caution to patients treated with TCAs. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.indinavirindinavir will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ipratropiumipratropium and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isofluraneisoflurane and trimipramine both increase QTc interval. Use Caution/Monitor.isoniazidtrimipramine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.isoproterenoltrimipramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.istradefyllineistradefylline will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.itraconazoleitraconazole will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ketamineketamine and trimipramine both increase sedation. Use Caution/Monitor.ketoconazoleketoconazole will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ketotifen, ophthalmictrimipramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.L-tryptophantrimipramine and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.lapatinibtrimipramine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.lasmiditanlasmiditan, trimipramine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.trimipramine increases effects of lasmiditan by serotonin levels. Use Caution/Monitor. Coadministration may increase risk of serotonin syndrome.lemborexantlemborexant, trimipramine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.lenacapavirlenacapavir will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.levalbuteroltrimipramine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levofloxacintrimipramine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.levoketoconazolelevoketoconazole will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.levorphanollevorphanol and trimipramine both increase sedation. Use Caution/Monitor.levothyroxinelevothyroxine increases effects of trimipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.liothyronineliothyronine increases effects of trimipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.liotrixliotrix increases effects of trimipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.lisdexamfetaminetrimipramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trimipramine, lisdexamfetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s).lithiumtrimipramine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.lithium and trimipramine both increase QTc interval. Use Caution/Monitor.lofepraminelofepramine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.lofepramine and trimipramine both increase sedation. Use Caution/Monitor.lofexidinetrimipramine and lofexidine both increase sedation. Use Caution/Monitor.trimipramine decreases effects of lofexidine by unspecified interaction mechanism. Use Caution/Monitor.lopinavirlopinavir will increase the level or effect of trimipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.loprazolamloprazolam and trimipramine both increase sedation. Use Caution/Monitor.lorazepamlorazepam and trimipramine both increase sedation. Use Caution/Monitor.lorcaserinlorcaserin will increase the level or effect of trimipramine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.lormetazepamlormetazepam and trimipramine both increase sedation. Use Caution/Monitor.loxapineloxapine and trimipramine both increase sedation. Use Caution/Monitor.loxapine inhaledloxapine inhaled and trimipramine both increase sedation. Use Caution/Monitor.lsdtrimipramine and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.lumacaftor/ivacaftorlumacaftor/ivacaftor, trimipramine. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C19 substrates. .lurasidonelurasidone, trimipramine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.lurasidone, trimipramine. Either increases